Key result
This review summarizes the current evidence base for short-term dual antiplatelet therapy following percutaneous coronary intervention, including the role of bioengineered stents.
Why the study?
Reducing DAPT duration to 1-3 months in high bleeding risk patients has low-level evidence, while clinical practice sometimes requires stopping DAPT in under 30 days.
Answers are grounded in this paper and cite their sources.
This review summarizes the evidence base for reduced duration of dual antiplatelet therapy after PCI, highlighting the role of bioengineered stents and optical coherence tomography.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Тарасов et al. (2021) conducted a review in Coronary artery stenting. Short-term dual antiplatelet therapy was evaluated. This review summarizes the current evidence base for short-term dual antiplatelet therapy following percutaneous coronary intervention, including the role of bioengineered stents.
Synapse has enriched 10 related papers. Consider them for comparative context: